Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation

<p>SNP ID.</p>

Bewaard in:

Bibliografische gegevens
Hoofdauteur:	Francesca Orzan (15055579) (author)
Andere auteurs:	Francesca De Bacco (15055582) (author), Elisabetta Lazzarini (15055585) (author), Giovanni Crisafulli (15055588) (author), Alessandra Gasparini (15019568) (author), Angelo Dipasquale (15055591) (author), Ludovic Barault (15030747) (author), Marco Macagno (15030744) (author), Pasquale Persico (15055594) (author), Federico Pessina (15055597) (author), Beatrice Bono (15055600) (author), Laura Giordano (15055603) (author), Pietro Zeppa (15055606) (author), Antonio Melcarne (15055609) (author), Paola Cassoni (15055612) (author), Diego Garbossa (15055615) (author), Armando Santoro (15034235) (author), Paolo M. Comoglio (15055618) (author), Stefano Indraccolo (15027102) (author), Matteo Simonelli (15055621) (author), Carla Boccaccio (15055624) (author)
Gepubliceerd in:	2025
Onderwerpen:	Cancer Therapeutic Research and Development Methods and Technology CNS Cancers Gliomas, Glioblastomas Liquid Biopsy Translational Research
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
door: Francesca Orzan (15055579)
Gepubliceerd in: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
door: Francesca Orzan (15055579)
Gepubliceerd in: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
door: Michael Kilian (16697663)
Gepubliceerd in: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
door: Michael Kilian (16697663)
Gepubliceerd in: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
door: Michael Kilian (16697663)
Gepubliceerd in: (2025)

Supplementary Table S1 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
door: Mengjie Zhao (14845174)
Gepubliceerd in: (2025)

Supplementary Table S2 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
door: Mengjie Zhao (14845174)
Gepubliceerd in: (2025)

Supplementary Table S4 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
door: Mengjie Zhao (14845174)
Gepubliceerd in: (2025)

Supplementary Table S5 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
door: Mengjie Zhao (14845174)
Gepubliceerd in: (2025)

Supplementary Table S8 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
door: Mengjie Zhao (14845174)
Gepubliceerd in: (2025)

Supplementary video from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
door: Min Wu (14962986)
Gepubliceerd in: (2025)

Table S1 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
door: Min Wu (14962986)
Gepubliceerd in: (2025)

Table S2 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
door: Min Wu (14962986)
Gepubliceerd in: (2025)

Table S3 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
door: Min Wu (14962986)
Gepubliceerd in: (2025)

Supplementary Data File 1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
door: William Kelly (15439117)
Gepubliceerd in: (2025)

Supplementary Data File 2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
door: William Kelly (15439117)
Gepubliceerd in: (2025)

Data Sheet 3_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
door: Hailong Pang (12841991)
Gepubliceerd in: (2025)

Data Sheet 2_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
door: Hailong Pang (12841991)
Gepubliceerd in: (2025)

Data Sheet 1_Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.pdf
door: Hailong Pang (12841991)
Gepubliceerd in: (2025)

Table S1 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
door: N. Ari Wijetunga (15056183)
Gepubliceerd in: (2025)

Table S2 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
door: N. Ari Wijetunga (15056183)
Gepubliceerd in: (2025)

Table S3 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
door: N. Ari Wijetunga (15056183)
Gepubliceerd in: (2025)

Table S4 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
door: N. Ari Wijetunga (15056183)
Gepubliceerd in: (2025)

Supplementary Figure S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
door: Kala Visvanathan (14952973)
Gepubliceerd in: (2025)

Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
door: Kala Visvanathan (14952973)
Gepubliceerd in: (2025)

Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
door: Kala Visvanathan (14952973)
Gepubliceerd in: (2025)

Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
door: Kala Visvanathan (14952973)
Gepubliceerd in: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
door: Kala Visvanathan (14952973)
Gepubliceerd in: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
door: Sied Kebir (15048732)
Gepubliceerd in: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
door: Sied Kebir (15048732)
Gepubliceerd in: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
door: Sied Kebir (15048732)
Gepubliceerd in: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
door: Sied Kebir (15048732)
Gepubliceerd in: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
door: Sied Kebir (15048732)
Gepubliceerd in: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
door: Defne Bayik (14961098)
Gepubliceerd in: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
door: Qingsheng Xu (17078830)
Gepubliceerd in: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
door: Qingsheng Xu (17078830)
Gepubliceerd in: (2025)

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
door: Joseph Toker (15399882)
Gepubliceerd in: (2025)

Cannot write session to /tmp/vufind_sessions/sess_etdhb019vt0oaq7a3qv9qc7889